IMMUNOTHERAPY

In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.

Bradley J. Monk, MD, FACOG, FACS, discusses the use of immune checkpoint inhibitors to treat cervical cancer.

As part of the larger Resound trial, regorafenib met its primary endpoint in thymic cancer but no patient subset received greater benefits from the drug.

According to Ajjai S. Alva, MBBS, CDK12 is a cell cycle gene that has an important role in RNA polymerase 2 and immunotherapy activity.

Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.

BNT111, an immunotherapy agent under investigation in a phase 2 study, has been granted fast track designation by the FDA.

Novel immuno-oncology agent, COM701 in combination with nivolumab and BMS-986207 may be safe for the treatment of patients with advanced solid tumors.

Phase 2 results presented during the SITC Annual Meeting show that adding intratumoral BO-112 to pembrolizumab in patients with advanced melanoma can induce durable responses.

The biopsy of a 88-year-man demonstrated infiltrative basal cell carcinoma. his case was the topic of discussion during a Case-Based Roundtable led by Nikhil I. Khushalani, MD.

The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.

Immune checkpoint inhibitors an induce resistance through activation of additional immune checkpoints such as LAG-3. Research around LAG3 will be important for the future.

Even after more than a decade, the uses of immune checkpoint inhibitors continue to expand across both solid and hematologic malignancies, further adding to the excitement over immuno-oncology.

Developing modern strategies to predict and accurately monitor treatment response remains an important piece of the clinical management puzzle.

After success in malignant melanoma and non–small cell lung cancer, adjuvant treatments are demonstrating improvements in disease-free survival in other cancers, including renal cell carcinoma, esophageal/gastroesophageal cancer, and breast cancer.

According to David T. Teachey, MD, newly developed therapies have improved remission rates in T-ALL and B-ALL.

The phase 2 NOVA-II study has completed its part 1 analysis of OQL011 for the treatment of cancer therapy-induced skin toxicities.

Retrospective data show a low prevalence of esophagitis among immune checkpoint inhibitor-related adverse event in patient with cancer.

In an interview with Targeted Oncology, Rodney P. Rocconi, MD, FACOG, discussed the analysis of the homologous recombination proficient patients with advanced-stage ovarian cancer treated in the phase 2 VITAL study as well as a biomarker analysis.

In an interview with Targeted Oncology, Marc Ernstoff, MD, discussed the significance of the SITC clinical practice guideline for managing immune-related adverse events.

The high prevalence of bone metastases in non–small cell lung cancer led 2 institutions to investigate how these metastases impact survival in patients treated with immune checkpoint inhibitors.

In the wake of immunotherapy combinations becoming available in breast cancer, including triple-negative breast cancer, the Society for Immunotherapy of Cancer has published clinical practice guidelines for physicians treating in this setting.

The Association of Community Cancer Centers released the results of their 2020 ACCC IO survey that showed how oncology professionals are looking to understand and take advantage of the growing immunotherapy treatment landscape.

Ronald J. Scheff, MD, reviews the molecular testing practices for non–small cell lung cancer and frontline treatment of patients with PD-L1-positive non–small cell lung cancer during a Case-Based Roundtable event.

Based on a review of immune checkpoint inhibitor mechanisms of action and clinical trial data, SITC has published a clinical practice guideline, which provides key recommendations for managing immune-related adverse events.

T-cell–targeted immunomodulators burst onto the scene a decade ago, and investigators turned their focus to immune checkpoints such as CTLA-4, PD-1, and PD-L1 to develop new cancer-fighting strategies.

Maurie Markman, MD, addresses different treatment options, including checkpoint inhibitors, for patients with endometrial cancer.

As June is Cancer Immunotherapy Month, Mehmet Akce, MD, discusses the future of immunotherapy in HCC in an interview with Targeted Oncology.

An excerpt from the Targeted Talks highlights the interest in PD-1/PD-L1 and CTLA-4 antibodies, their mechanisms of action, and the potential they bring to the immunotherapy field.

As numerous approvals across cancer settings and emerging approaches are explored in clinical research, new findings presented at the 2021 American Society of Clinical Oncology Annual Meeting in June continue to encourage investigators.

While the volume and variety of information coming from current studies seems overwhelming, it is what is changing the cancer care environment today.